{
    "2018-05-07": [
        [
            {
                "time": "2018-04-25",
                "original_text": "Lilly Declares Second-Quarter 2018 Dividend",
                "features": {
                    "keywords": [
                        "dividend",
                        "second-quarter",
                        "lilly"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-05-03",
                "original_text": "What's in Store for Radius Health (RDUS) in Q1 Earnings?",
                "features": {
                    "keywords": [
                        "radius health",
                        "q1 earnings",
                        "rdus"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-30",
                "original_text": "Alimta: An Emerging Drug to Treat Lung Cancer",
                "features": {
                    "keywords": [
                        "alimta",
                        "lung cancer",
                        "emerging drug"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-05-01",
                "original_text": "Allergan’s Valuations after Its 1Q18 Earnings",
                "features": {
                    "keywords": [
                        "allergan",
                        "valuations",
                        "1q18 earnings"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-28",
                "original_text": "Verzenio: Major CDK4/6 Inhibitor in the Future",
                "features": {
                    "keywords": [
                        "verzenio",
                        "cdk4/6 inhibitor",
                        "future"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-27",
                "original_text": "Taltz: Therapy for Psoriasis Indication",
                "features": {
                    "keywords": [
                        "taltz",
                        "psoriasis",
                        "therapy"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-05-02",
                "original_text": "How Celgene Performed in 1Q18",
                "features": {
                    "keywords": [
                        "celgene",
                        "performance",
                        "1q18"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "See what the IHS Markit Score report has to say about Eli Lilly And Co.",
                "features": {
                    "keywords": [
                        "ihs markit score",
                        "eli lilly",
                        "report"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-01",
                "original_text": "Allergan’s US General Medicines Segment in 1Q18",
                "features": {
                    "keywords": [
                        "allergan",
                        "us general medicines",
                        "1q18"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}